By Melanie Senior
Shire Pharmaceuticals Group PLC 's proposed $1.6 billion cash acquisition of Transkaryotic Therapies Inc. took the markets by...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?